2.7.11.30 A78G site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 D89A site-directed mutagenesis, the mutation does not affect binding of actividin 665487 2.7.11.30 E74A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 E88A site-directed mutagenesis, the mutation does not affect binding of actividin 665487 2.7.11.30 F82A site-directed mutagenesis, the mutation slightly affects binding of actividin 665487 2.7.11.30 G79A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 H312Q naturally occuring mutation in Japanese pulmonary arterial hypertension patients 691833 2.7.11.30 I70A site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant 665487 2.7.11.30 K222R inactive mutant 665532 2.7.11.30 K72A site-directed mutagenesis, the mutation does not affect binding of actividin 665487 2.7.11.30 K80A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 L381P naturally occuring mutation in Japanese pulmonary arterial hypertension patients 691833 2.7.11.30 L40A site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant 665487 2.7.11.30 L75A site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant 665487 2.7.11.30 L85A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 L90A site-directed mutagenesis, the mutation does not affect binding of actividin 665487 2.7.11.30 M53A site-directed mutagenesis, the mutation slightly affects binding of actividin 665487 2.7.11.30 additional information activin receptor-like kinase 6 Booroola mutation enhances suppressive effects of bone morphogenetic protein 2, BMP2, BMP4, BMP6 and growth and differentiation factor-9 on FSH release from ovine primary pituitary cell cultures 693381 2.7.11.30 additional information ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients, determination of polymorphisms in Japanese pulmonary arterial hypertension patients, phenotypes, overview 691833 2.7.11.30 additional information conferring of responsiveness to GDF-9-mediated stimulation of ALK5 and Smad3 phosphorylation in normally unresponsive COS-7 cells by overexpression of the three proteins, no responsiveness by co-expression with BMPRII receptor, expression of GDF-9 in a CAGA-luciferase reporter construct in P19 cells reveals that GDF-9 binds to BMP-activated type II receptors but its downstream actions are mediated by the type I receptor ALK5, overview, expression of ALK5 siRNA inhibits GDF-9-induced stimulation in granulosa cells 666359 2.7.11.30 additional information construction of a truncated dominant negative ALK4 mutant 665487 2.7.11.30 additional information construction of a truncated mutant ALK7 664282 2.7.11.30 additional information expression of HA-tagged wild-type ALK7 in rat FaO hepatoma cells and transiently of HA-tagged ALK mutant T194D in human Hep3B hepatoma cells using the adenovirus infection method, expression leads in both cases to an apoptosis-positive phenotype, expression of inactive ALK7 mutant K222R dos not cause an altered phenotype 665532 2.7.11.30 additional information functional co-expression of TGF-beta and the soluble intracellular domain of the TGF-beta type I receptor in murine mammary gland epithelial cells induces transdifferentiation of epithelial cells to mesenchymal cells, overview 663984 2.7.11.30 additional information knockdown of ALK5 expression in embryonic endothelial cells by antisense oligonucleotides results in inhibition of both TGF-beta-induced Smad 2 and Smad1/5 phosphorylation, an ALk5mutant defective in Smad activation rescues TGF-beta/ALK1-induced signaling in ALK5 null mutant endothelial cells 666312 2.7.11.30 additional information knockout of TBRI by shRNA suppression using a lentiviral construct leads to decreased smad2 activtaion and reverses the suppressive effects of TGF-beta on hematopoiesis, overview 691460 2.7.11.30 additional information misexpression of ALK2 in nontransforming ventricular, endocardial cells causes epithelial-mesenchymal transformation, EMT, which can be decreased by overexpression of inhibitor Smad6 664715 2.7.11.30 P71A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 P77A site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant 665487 2.7.11.30 P81A site-directed mutagenesis, the mutation does not affect binding of actividin 665487 2.7.11.30 Q201D constitutively active ALK1 mutant 665699 2.7.11.30 R479Q naturally occuring mutation in Japanese pulmonary arterial hypertension patients 691833 2.7.11.30 R484Q naturally occuring mutation in Japanese pulmonary arterial hypertension patients 691833 2.7.11.30 R91A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 S38A site-directed mutagenesis, the mutation slightly affects binding of actividin 665487 2.7.11.30 S55A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 S86A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 S87A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 T194D constitutive active ALK7 mutant 665532 2.7.11.30 T194D site-directed mutagenesis of ALK7 690773 2.7.11.30 T202D site-directed mutagenesis 740796 2.7.11.30 T204D constitutively active ALK5 mutant 664088 2.7.11.30 T93A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 V73A site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant 665487 2.7.11.30 V76A site-directed mutagenesis, the mutation affects binding of actividin 665487 2.7.11.30 Y83A site-directed mutagenesis, the mutation affects binding of actividin 665487